The pathogenic role of calcitonin gene-related peptide and predictors of new-onset migraine and long-term outcomes after transcatheter atrial septal defect closure.

Researchers studied 212 patients (mostly young women) who underwent a minimally invasive procedure to close a heart defect called an atrial septal defect (ASD). They wanted to understand why some people develop new migraine headaches after this procedure. About 20% of patients developed new migraines after their heart procedure, which is an important finding for anyone considering this treatment.

The study measured specific substances in the blood called neuropeptides, particularly calcitonin gene-related peptide (CGRP), which is known to be involved in migraine development. Researchers found that CGRP levels increased significantly after the procedure in patients who developed new migraines, suggesting this substance plays a role in causing these headaches. Younger patients, those with larger heart defects, and those who had some continued blood flow through the repair site were more likely to develop migraines.

The long-term news was concerning: when researchers followed up with patients about 14 years later, nearly half still experienced migraines that never went away. These patients with persistent migraines tended to have had more significant heart defects before their procedure.

While this study focused on understanding why migraines develop after heart procedures rather than treating them, the findings about CGRP are relevant because acupuncture has been shown in other research to help regulate CGRP levels and may offer a drug-free option for migraine management. If you're experiencing migraines after an ASD closure procedure, consult with a licensed acupuncturist experienced in treating headache disorders.

This prospective cohort study (n=212, median age 21 years, 75.9% female) investigated new-onset migraine (NOM) following transcatheter ASD closure between 2001-2013. NOM occurred in 20.3% of patients. Plasma CGRP levels measured via ELISA increased significantly post-procedure in NOM patients (47.9 vs. 38.0 pg/mL, p=0.023), while NPY levels showed no significant change. Multivariate analysis identified three independent predictors: younger age (aOR 0.98, 95% CI 0.96-0.99), larger ASD size (aOR 1.07, 95% CI 1.01-1.14), and transient residual shunting (aOR 2.78, 95% CI 1.05-7.36). At median 14-year follow-up, 48.1% experienced unremitting migraine, associated with smaller device-to-ASD ratio and larger Qp/Qs ratio pre-closure. Clinical significance: CGRP elevation post-procedure suggests a pathogenic mechanism that may respond to treatments targeting CGRP modulation, including acupuncture, which has demonstrated CGRP-regulatory effects in migraine management.